A Single-center, Open-label, Phase 1 Study of Macitentan, Radiotherapy and Temozolomide Concurrent Therapy Followed by Maintenance Therapy With Macitentan and Temozolomide in Subjects With Newly Diagnosed Glioblastoma

Trial Profile

A Single-center, Open-label, Phase 1 Study of Macitentan, Radiotherapy and Temozolomide Concurrent Therapy Followed by Maintenance Therapy With Macitentan and Temozolomide in Subjects With Newly Diagnosed Glioblastoma

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Macitentan (Primary) ; Temozolomide
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 06 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 26 Sep 2016 Planned End Date changed from 1 Jul 2017 to 1 Nov 2016.
    • 26 Sep 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top